Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 18.
doi: 10.1002/ccd.70185. Online ahead of print.

Complete Revascularization Versus Culprit-Only PCI in Acute Coronary Syndrome and Multivessel Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis of 10,150 Subjects From 11 Randomized Studies

Dario Calderone  1 , Giuseppe Verolino  1   2 , Alessandro Cianca  3 , Giuseppe Migliario  4 , Davide Sala  1 , Paolo Ghiso Basile  1 , Roberto Adriano Latini  1 , Paolo Sganzerla  1 , Gianfranco Parati  5   6
Affiliations

Complete Revascularization Versus Culprit-Only PCI in Acute Coronary Syndrome and Multivessel Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis of 10,150 Subjects From 11 Randomized Studies

Dario Calderone et al. Catheter Cardiovasc Interv. .

Abstract

Background: Approximately half of individuals with acute coronary syndrome (ACS) are affected by multivessel coronary artery disease (CAD), and recent studies in the field have presented conflicting data on effective benefit of complete revascularization. The aim of this study was to investigate the efficacy and safety of multivessel percutaneous coronary intervention (PCI) versus culprit-only PCI in individuals presenting with acute coronary syndrome and multivessel CAD.

Methods and results: Randomized trials on ACS comparing multivessel PCI versus culprit-only PCI were included. The primary efficacy outcome was all-cause death. The primary safety outcomes were major bleeding and contrast induced nephropathy. Secondary ischemic and safety outcomes were also investigated. Subgroup analyses were conducted to investigate the consistency of the effect sizes as a function of age (younger vs older individuals, using a cut-off of 65 years) and of a higher or lower prevalence of diabetic patients (using a cut-off of 20% for each study). A total of 11 randomized trials including 10,150 individuals with a mean follow-up of 21.7 months were included. Compared with cluprit-only PCI, multivessel PCI significantly reduced the risk of all-cause death (risk ratio 0.86, [0.74-1.00], p = 0.047), mainly due to a significant reduction in cardiovascular mortality by 26%. Similarly, the rates of new myocardial infarction and unplanned revascularization were significantly reduced. No increases in major bleeding, contrast induced nephropathy or stroke were observed, with a significantly higher rate of stent thrombosis in complete revascularization group, even if with a low absolute risk (risk ratio 1.69 [1.10, 2.59], p = 0.027). Subgroup analyses revealed a significant interaction for death in studies with higher prevalence of diabetics (p for interaction = 0.029), but no interaction for death with regards of age.

Conclusion: In individuals presenting with ACS and multivessel CAD, complete revascularization was associated with a significant reduction in all-cause mortality, with a lower rate of major ischemic events and no significant increase in major complications. The benefit was particularly evident in diabetic patients.

PubMed Disclaimer

References

    1. D.‐W. Park, R. M. Clare, P. J. Schulte, et al., “Extent, Location, and Clinical Significance of Non–Infarct‐Related Coronary Artery Disease Among Patients With ST‐Elevation Myocardial Infarction,” Journal of the American Medical Association 312 (2014): 2019.
    1. R. A. Byrne, X. Rossello, J. J. Coughlan, et al., “2023 ESC Guidelines for the Management of Acute Coronary Syndromes,” European Heart Journal 44 (2023): 3720–3826.
    1. D. C. Faro, C. Laudani, F. G. Agnello, et al., “Complete Percutaneous Coronary Revascularization in Acute Coronary Syndromes With Multivessel Coronary Disease,” JACC: Cardiovascular Interventions 16 (2023): 2347–2364.
    1. C. Laudani, G. Occhipinti, A. Greco, M. Spagnolo, D. Giacoppo, and D. Capodanno, “Completeness, Timing, and Guidance of Percutaneous Coronary Intervention for Myocardial Infarction and Multivessel Disease: A Systematic Review and Network Meta‐Analysis,” EuroIntervention 21 (2025): e203–e216.
    1. V. Atti, Y. Gwon, M. A. Narayanan, et al., “Multivessel Versus Culprit‐Only Revascularization in STEMI and Multivessel Coronary Artery Disease,” JACC: Cardiovascular Interventions 13 (2020): 1571–1582.